BioPlus Acquisition Corp. financial data

Location
260 Madison Avenue, Suite 800, New York, NY
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2023 - Aug 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52.1 %
Debt-to-equity -103 %
Return On Equity -38.1 % -1168%
Return On Assets 2.71 %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 230M USD

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -2.16M USD -207%
Net Income (Loss) Attributable to Parent 5.79M USD +4878%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 197K USD -72.5%
Assets 139M USD -41.2%
Accrued Liabilities, Current 409K USD +69.3%
Liabilities, Current 1.98M USD +719%
Liabilities 16.8M USD +11.6%
Retained Earnings (Accumulated Deficit) -16.6M USD -17%
Stockholders' Equity Attributable to Parent -16.6M USD -17%
Liabilities and Equity 139M USD -41.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -316K USD -89.6%
Net Cash Provided by (Used in) Financing Activities 211K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -105K USD +45.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.45K USD -99.2%
Cash and Cash Equivalents, Period Increase (Decrease) -193K USD -871%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%